EA2251: what clinicians are saying
ivonescimab in advanced biliary tract cancer · NCT07765433 ↗ · Phase 2/Phase 3 · ECOG-ACRIN Cancer Research Group
A medical oncologist looks to EA2251 for clarity on the bispecific’s contribution because HARMONi-GI1 lacked a PD-L1-plus-bevacizumab arm, though that capability is unproven. Direct commentary is limited; HARMONi-GI1 provides context, not outcomes from the US study. Its reported survival benefit is qualified by accounts of greater high-grade toxicity. In that context, the same oncologist questions another medical oncologist’s unconditional prediction of pan-tumor blockbuster status for ivonescimab, citing interim evidence. Final survival and quality-of-life data remained pending.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 28 verified statements
This edition $750, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. GI1: most speakers value active control; a clinician asks what the bispecific adds
1 of the report's 3 cited clinicians · 7 statements from 3 speakers in 6 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Overall survival (OS), Population and setting, Secondary endpoints, Design and conduct, Safety and tolerability.
02. EA2251: what speakers say
No named clinician · accounts and unnamed speakers · 8 statements from 1 speaker in 5 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 2.
Draws on: Design and conduct, Population and setting, Primary endpoint: Overall survival (OS), Secondary endpoints, The comparison, Safety and tolerability.
Beyond the trial population
03. Ivonescimab in HARMONi-GI1: what speakers say
No named clinician · accounts and unnamed speakers · 5 statements from 1 speaker in 5 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 3.
04. HARMONi-GI1 evidence: where speakers split on scrutiny of China-only interim data
1 of the report's 3 cited clinicians · 6 statements from 3 speakers in 6 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 2.
05. Ivonescimab: where speakers split on pan-tumor expectations after interim GI1
2 of the report's 3 cited clinicians · 4 statements from 3 speakers in 3 sources · 4 passages
Limitations recorded: 2.
06. OS hazard-ratio rankings: why a speaker weighs cancer context and options
No named clinician · accounts and unnamed speakers · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
1 of the report's 3 cited clinicians
GI1: most speakers value active control; a clinician asks what the bispecific adds
7 statements from 3 speakers in 6 sources, 1 of them a podcast or video
2 of the 3 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician asks what the bispecific adds”
- 7
- statements
- 6
- passages
- 6
- sources
- 3
- speakers
What the statements areViews 3Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 3Statement-to-passage links (a passage can back several statements)Supporting a statement 7Giving context 1Recorded with the findingLimitations: 2
5 posts and articles · 1 podcast or video
Draws on: The comparison, Primary endpoint: Overall survival (OS), Population and setting, Secondary endpoints, Design and conduct, Safety and tolerability.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
4 of the 6 findings and 10 of the 28 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (5)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PD-L1, programmed death-ligand 1.
The full EA2251 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What evidence do clinicians say they need on ivonescimab’s bispecific contribution and applicability beyond China before using it with chemotherapy instead of durvalumab plus chemotherapy for first-line advanced biliary tract cancer?
From finding F1 (7 statements from 3 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 29commentary sources screened
- 12sources cited by verified statements
- 6named in screened sources
- 5speakers cited in the report
- 4cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 3 physician, Medical oncology
Also in the sources: 4 organizational or shared accounts, not counted as people.
- 28verified statements, each linked to its source
- 4of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 28 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 12 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall survival (OS) | 13 | 10 |
| Secondary endpoints | 6 | 5 |
| Population and setting | 12 | 9 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 7 | 5 |
| Safety and tolerability | 5 | 5 |
| Design and conduct | 5 | 5 |
| Evidence maturity and additional information requested | 6 | 6 |
| Country-of-origin scrutiny and access | 1 | 1 |
| Regulatory status, local availability and patient counseling | 6 | 3 |
| Pan-tumor extrapolation and class-level interest | 3 | 3 |
| Cross-trial rankings and clinical value | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
28 verified statements from 12 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 7 statements · 25% | ||||
| YouTube | 7 | 1 | 1 | |
| Posts · 21 statements · 75% | ||||
| X threads | 18 | 9 | 20 | |
| LinkedIn posts | 2 | 1 | 1 | |
| Bluesky threads | 1 | 1 | 7 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 22 / quarter
- Screened window
- Aug 16, 2026 → Nov 10, 2026
- Cited window
- Aug 26, 2026 → Nov 10, 2026
- Retrieved
- Nov 22, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer
- Registry
- NCT07765433
- Study IDs
- EA2251 · NCI-2026-04569 (CTRP (Clinical Trial Reporting Program)) · U10CA180820
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Collaborators
- National Cancer Institute (NCI)
- Design
- Phase 2/Phase 3 · Interventional, randomized, parallel
- Status
- Not yet recruiting
- Enrollment
- 336 estimated
- Registered
- 2026-08-14
- Start
- 2027-01-11 estimated
- Primary completion
- 2028-12-31 estimated
- Primary endpoint
- Overall survival (OS)
- Interventions
- 8 registered
More on: Biliary tract cancer, ivonescimab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 24 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 34 sources about other trials or topics are not included.
- Most substantive efficacy and safety commentary concerns HARMONi-GI1 as evidence for the same first-line decision, not outcomes observed in EA2251.
- No EA2251 protocol or publication reporting its outcomes was identified in the sources reviewed for this edition. The comments therefore cannot independently resolve expectations about which treatment contribution EA2251 could isolate.
Show all 7 known gaps +Fewer −
- The sources include corporate communication and repeated summaries of release-derived information. Their number cannot be interpreted as a number of independent HCP opinions or as the prevalence of a view.
- Only part of the relevant regulatory material was reviewed. Approval, availability and development forecasts remain dated source statements rather than a complete or current regulatory assessment.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. EA2251 (NCT07765433): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/ea2251-nct07765433
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "EA2251" (NCT07765433), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "ea2251-nct07765433". If you cannot make requests, read https://www.erudio.com/reports/ea2251-nct07765433.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07765433", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07765433 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/ea2251-nct07765433.json
curl https://www.erudio.com/reports/ea2251-nct07765433.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "ea2251-nct07765433" })release 8acb8d077dad8f4b454d4ee35d2d2e11c2ac809bfdadf963ca1e080ced8fc1a7
Questions
How much does the EA2251 report cost?
One edition costs $750 (Focused · 28 verified statements · 4 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the EA2251 report cover?
28 statements from 12 sources (1 video, 11 posts), 4 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the EA2251 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "ea2251-nct07765433" }) previews it and create_order({ "report": "ea2251-nct07765433", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the EA2251 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.